News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio3 Research And Creabilis Therapeutics Sign Research Agreements With Cephalon, Inc. (CEPH) Research Will Focus On Potential New Treatments For Psoriasis And Restenosis


12/1/2005 12:31:44 PM

COLLERETTO GIACOSA (Turin), Italy, and MILAN, Italy--(BUSINESS WIRE)--Dec. 1, 2005--Bio3 Research S.r.l., and Creabilis Therapeutics S.p.A. announced agreements with Cephalon, Inc. to evaluate the research compound K252a for its potential to topically treat psoriasis and for potential use in the prevention and treatment of restenosis. Creabilis Therapeutics owns patent applications covering K252a-based products for the treatment of psoriasis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES